Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nutex Health Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on October 21, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Nutex securities between August 8, 2024, and August 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. Group 2: Case Allegations - The lawsuit alleges that Nutex made false and misleading statements regarding its financial practices and internal controls, particularly concerning its relationship with HaloMD, a third-party vendor [4]. - Specific claims include that Nutex engaged in fraudulent activities to inflate revenues, overstated its ability to remediate internal control weaknesses, and improperly classified stock-based compensation obligations [4]. - The lawsuit asserts that these misrepresentations led to an overstatement of Nutex's business and financial prospects, resulting in investor damages when the truth was revealed [4].

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for violations of federal securities laws, impacting investors who acquired Nutex securities during the specified Class Period from August 8, 2024, to August 14, 2025 [1][2]. Group 1: Allegations Against Nutex - The lawsuit alleges that Nutex and its officers made false and misleading statements regarding the company's financial practices and internal controls [2]. - Specific claims include that Nutex engaged in fraudulent activities through HaloMD, leading to unsustainable revenue and improper accounting of stock-based compensation obligations [2]. - The company is accused of overstating its financial prospects and failing to disclose material weaknesses in its internal controls over financial reporting [2]. Group 2: Impact on Investors - Following the revelation of these allegations, Nutex's common stock experienced a significant decline, resulting in financial losses for investors [3]. - Investors who suffered losses exceeding $50,000 are encouraged to participate in the lawsuit, with a deadline to act as Lead Plaintiff set for October 21, 2025 [3]. Group 3: About the Law Firm - Lowey Dannenberg P.C. is a law firm specializing in representing institutional and individual investors who have suffered financial losses due to corporate fraud and violations of federal securities laws [4]. - The firm has a track record of prosecuting multi-million-dollar lawsuits and has recovered billions for its clients [4].

Core Viewpoint - Nutex Health Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 8, 2024, and August 14, 2025, impacting investors adversely [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Nutex Health Inc. made false statements and concealed information regarding its third-party vendor HaloMD, which allegedly engaged in fraudulent activities to defraud insurance companies [2]. - It is alleged that revenues from Nutex's engagement with HaloMD were unsustainable due to the fraudulent nature of the conduct [2]. - The company reportedly overstated its remediation of material weaknesses in internal controls over financial reporting, leading to improper accounting of stock-based compensation obligations [2]. - As a result of these issues, Nutex Health Inc. faced increased risks of failing to file financial reports with the SEC in a timely manner, and its business and financial prospects were overstated [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - Nutex Health Inc. is facing legal scrutiny due to a class-action lawsuit alleging deceptive billing practices that artificially inflated its financial results [1][10]. Group 1: Legal Allegations - The lawsuit claims Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and causing significant financial losses [1][2]. - Allegations include a systematic effort to exploit the insurance arbitration process, submitting thousands of questionable claims to extract excessive reimbursements [2][4]. - The complaint asserts that Nutex's revenue model is unstable and that financial statements misrepresented the company's operations [3]. Group 2: Market Reaction - Following the release of a report by Blue Orca Capital accusing HaloMD of fraud, Nutex's stock dropped over 10%, indicating investor concern [4][5]. - After Nutex delayed its Form 10-Q submission, shares plummeted 16.39% the next day, closing at $92.91 [7]. Group 3: Financial Reporting Issues - The lawsuit highlights misrepresentation in Nutex's financial controls, particularly regarding the classification of stock-based compensation obligations [6]. - On August 21, Nutex disclosed that its Audit Committee found prior financial statements required restatement due to incorrect classification of obligations related to hospital development [8]. Group 4: Investor Impact - The class-action suit seeks damages for investors who acquired Nutex securities during the alleged misrepresentation period, arguing that public disclosures were materially misleading [10][11]. - Hagens Berman is investigating whether Nutex's business model relied on questionable arbitration tactics and if its financial reporting misled investors [12].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Nutex Health Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by October 21, 2025 [3]. Group 1: Allegations Against Nutex - The complaint alleges that Nutex and its executives made false or misleading statements and failed to disclose critical information regarding their financial practices and relationships with third parties [5]. - Specific allegations include that Nutex engaged in a fraudulent scheme with HaloMD to defraud insurance companies, leading to unsustainable revenue claims [5]. - The company is accused of overstating its ability to remediate internal control weaknesses, which resulted in improper accounting for stock-based compensation obligations [5]. Group 2: Market Reaction - Following the release of a short report by Blue Orca Capital, Nutex's stock price fell by $11.18 per share, or 10.05%, closing at $100.01 on July 22, 2025 [7]. - After Nutex announced a delay in filing its Form 10-Q due to accounting adjustments, its stock price dropped further by $18.22 per share, or 16.39%, closing at $92.91 on August 15, 2025 [8]. Group 3: Legal Proceedings - Investors who purchased Nutex securities between August 8, 2024, and August 15, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1][3]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Nutex's conduct [10].

Core Viewpoint - Investors in Nutex Health Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged undisclosed fraudulent activities and financial misstatements by the company [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that from August 8, 2024, to August 14, 2025, Nutex Health Inc. failed to disclose that HaloMD was involved in a scheme to defraud insurance companies, leading to unsustainable revenue [2]. - The company is accused of overstating its remediation of material weaknesses in internal controls over financial reporting, which affected its ability to account for stock-based compensation obligations [2]. - Nutex allegedly misclassified stock-based compensation obligations as equity instead of liabilities, increasing the risk of delayed financial report filings with the SEC [2]. - Positive statements made by the company regarding its business and financial prospects were claimed to be materially misleading and lacked a reasonable basis [2].

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for alleged violations of securities laws, specifically related to misleading statements and fraudulent activities [1][4]. Group 1: Lawsuit Details - The lawsuit is initiated by the Schall Law Firm, focusing on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Nutex securities between August 8, 2024, and August 14, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Nutex - The complaint alleges that Nutex made false and misleading statements regarding its financial health and operations [4]. - Nutex is accused of engaging in a scheme with HaloMD to defraud insurance companies, leading to unsustainable revenue [4]. - The company reportedly overstated its internal controls and failed to accurately calculate stock-based compensation obligations, resulting in materially misleading public statements [4].

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for failing to disclose fraudulent activities by its third-party arbitration vendor, HaloMD, which has raised concerns about the legitimacy of the company's reported revenues and financial health [2][3]. Group 1: Allegations and Concerns - Nutex Health Inc. allegedly engaged in a scheme with HaloMD that defrauded insurance companies, leading to unsustainable revenue figures [2]. - The company is accused of overstating its ability to remediate internal control weaknesses, affecting its financial reporting and stock-based compensation calculations [2]. - A short report by Blue Orca Capital highlighted that Nutex's recent 20-fold share price surge was artificially inflated due to HaloMD's practices, raising doubts about the company's financial performance [3]. Group 2: Financial Impact - Following the announcement of a delay in filing quarterly financial statements due to incomplete accounting adjustments, Nutex's stock price dropped over 16% [4]. - The potential cessation of revenue benefits from HaloMD's billing practices could lead to a significant decline in Nutex's financial performance, possibly reverting its stock to penny-stock levels [3]. Group 3: Legal Proceedings - Shareholders are encouraged to participate in the class action lawsuit against Nutex Health Inc., with options to serve as lead plaintiff or remain an absent class member [5]. - Robbins LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless a recovery is achieved [6].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Nutex Health Inc. securities, alleging misleading statements and fraudulent activities during the Class Period from August 8, 2024, to August 14, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Nutex Health Inc. made false and misleading statements regarding its financial practices and internal controls, particularly related to its engagement with HaloMD, a third-party vendor [5]. - Allegations include that Nutex's revenues from HaloMD were unsustainable due to fraudulent conduct, and that the company overstated its ability to remediate internal control weaknesses [5]. - The lawsuit asserts that Nutex improperly classified stock-based compensation obligations, which increased the risk of failing to file timely financial reports with the SEC [5]. Group 2: Class Action Participation - Investors who purchased Nutex securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly [3][6]. - A lead plaintiff is needed to represent the class, and interested individuals must move the Court by October 21, 2025 [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4]. - Founding partner Laurence Rosen has received recognition as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [4].

Core Viewpoint - Nutex Health Inc. is facing a class action lawsuit due to allegations of misleading statements and fraudulent activities related to its financial reporting and arbitration processes [4]. Group 1: Company Performance and Stock Movements - Nutex's share price surged after it began submitting patient bills to arbitration for out-of-network medical bills, but subsequently fell by $11.18, or 10.1%, closing at $100.01 on July 22, 2025, following reports of a fraudulent scheme involving a third-party vendor [2]. - On August 14, 2025, Nutex announced a delay in filing its quarterly financial statements due to non-cash accounting adjustments, leading to a further decline in shares by $18.22, or 16.4%, closing at $92.91 on August 15, 2025 [3]. Group 2: Allegations in the Lawsuit - The class action lawsuit alleges that Nutex made materially false and misleading statements, failing to disclose that its arbitration results were achieved through a coordinated scheme to defraud insurance companies [4]. - It is claimed that revenues from Nutex's engagement with the third-party vendor were unsustainable and that the company overstated its ability to remediate weaknesses in its internal controls over financial reporting [4]. - The lawsuit also states that Nutex improperly classified stock-based compensation obligations, increasing the risk of failing to file financial reports with the SEC in a timely manner [4]. Group 3: Legal Proceedings - Investors who purchased Nutex securities during the class period (August 8, 2024, to August 14, 2025) have until October 21, 2025, to file a lead plaintiff motion in the class action lawsuit [1][5].